PM
TNYA icon

Prosight Management’s Tenaya Therapeutics TNYA Stock Holding History

Prosight Management’s Portfolio TNYA Stock Details TNYA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-107,063
Closed -$215K – 51
2022
Q4 		$215K Buy
+107,063
New +$261K 0.12% 39

Other funds holding TNYA

CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
ROTUOC
Regents of the University of California Oakland, California $3.01B AUM 11.91% 1-Year Est. Return

Prosight Management's TNYA Position: Q1 2023 in Review

Prosight Management sold out of Tenaya Therapeutics (TNYA) in Q1 2023, closing a stake of 107,063 shares — an estimated $215K sold.

Prosight Management first reported a position in TNYA in Q4 2022 and held it in 1 quarter. The position peaked at $215K in Q4 2022. 64 funds tracked by Wall St. Rank hold TNYA as of Q1 2023.

  • Prosight Management reported no remaining Tenaya Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Prosight Management sold 107,063 Tenaya Therapeutics shares in Q1 2023, an estimated $215K.
  • Prosight Management first reported a position in Tenaya Therapeutics in Q4 2022 and held it in 1 quarter.
  • Prosight Management's Tenaya Therapeutics position peaked at $215K in Q4 2022.
  • 64 funds tracked by Wall St. Rank held Tenaya Therapeutics as of Q1 2023.

Based on Prosight Management's 13F filing for Q1 2023, filed 12 May 2023.